pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-504 |
Genomic Coordinates | chrX: 138667711 - 138667793 |
Synonyms | MIRN504, hsa-mir-504, MIR504 |
Description | Homo sapiens miR-504 stem-loop |
Comment | The mature sequence shown here represents the most commonly cloned form from large-scale cloning studies . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-504-5p | |||||||||||||||
Sequence | 13| AGACCCUGGUCUGCACUCUAUC |34 | |||||||||||||||
Evidence | Experimental | |||||||||||||||
Experiments | Array-cloned | |||||||||||||||
SNPs in miRNA |
|
|||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ZNF814 | ||||||||||||||||||||
Synonyms | - | ||||||||||||||||||||
Description | zinc finger protein 814 | ||||||||||||||||||||
Transcript | NM_001144989 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ZNF814 | |||||||||||||||||||||
3'UTR of ZNF814 (miRNA target sites are highlighted) |
>ZNF814|NM_001144989|3'UTR 1 GTGTGAGGATTGTCAGAAAGTTTTTAGCAAGAAGGACCACCTCATTGCACACCAGAGAGTTCACACTGGAGAAAGGCCAT 81 ATGAATGCAGTGATTGTGGGAAGTCATCTACCCACAGCTCTGCATTCTGTGTTCATAAGAGAGTTCACACTGGTCACACC 161 ACCTTATGAGTGCAGTGAATGTGGGAAATCCTTTGCTGAAACTTTCAGTCTCATTAAACACAGGAGAGTTCACACTGGAG 241 TAAGGTCTTGTGATTGCAGCAAATGTGGGAAAAAAGTTACCTGAAGGTCTTTTCTCCTTGAATATCAGAGAGTTCACACT 321 AGACAAATAAAATACATTTGGGCAATTTTGTAGCCACACCTCTTTGCTCCTTCAAGATCAGAGTTAACACTGGATCAGGG 401 CCTTACCAGTGTGACATGTGAGATATTTATGTAGAAATCTAGCTTCATAACACACAGGAGACTTCCCACTGCAGAAATGC 481 CTTTTGAATGTAATGAATGCAAGAAAGCCTTCAGCCTTTTTATTGGAGCCTCAAACATTGACATGAGAAAAACACCATAG 561 ATGTATATGGAATGTTATTTCTTTTTCAATGTAACCCTTTGAGAGTGCCACCTACCTAGATTGAATGTCATTTATTGAGC 641 ATCTGCAAAAGTTCCAAGTGTGTGGCAGCTACAGTGCATTTTTCACTATACCCAGGTACCTTGCTAGATTTTTTTTGAGA 721 CAGGTTGTCACTGTGTCGCTCAGGATGGCGTGCAGTGGTGTGTTCACATTTCACTGCACCCTTGATCTGGGCTTAAGTGA 801 TTCTGTTGCCTCGGCCTCCTGAGTAGCTGAAACCACAGGCATGCACTACCATGCTCCACTAATTTTTTTAAGTTTTGGAG 881 AGACAGGGTCTCACCATGTTGCCCAGGCTGGTCTTAAACTCCTGGCTCAAGCGATCCTTCCACCTTGGCCTCCAAACATG 961 CTGGGATTACAGGTGTGAGTTACTGTGCCTGGCCTTTTTTTTTTTTTTTTTTAACTTTTAATTTCTGATCGAGTCACAGA 1041 AGGATTTGTTGAGTAGCTTCAGCACTTCTTCCTTTGTCATTTTTTTCTGTCTGATAAGTCATGCCATGGACGTTACCCAT 1121 TTTTATCCCAGAGGCCTCTTACGTTGACTTGAAAAGACGGACTATGTCTTTCAGAGATCTTGTGGGTATCACATCAATCT 1201 TGACAAATTTTCTACCCTCCAAGTCATGATCCTAAGAACAGCTTGCCTCCCATTTCTCCGGTTTGTGCTATTATGAAGGC 1281 CTTATTGTTTCAGCCTTCTTCAATCTTGAGGGTTGTTGTCACTGTATGGGTGGTTCAGAAATAAGTAGGTCCTGTTACTA 1361 TGAAGGGGGTCACAGCTTTTGTTGGCATAGCTAAACTTTGTGGCTCATGGAACAGTATGAATGCAGAATGTAGCTTTCTC 1441 CACTTGTGGACTGCTTTGCATAGCTGCCAGAGGCCTCCAGAGAAGACCTTCAGGGCTTTGTGGTCTTTATCTGTAGCACG 1521 GATACTAAAATTTGTGGGTTCATAGGTCAGCTGGATACAGGGCATTTTTTGTGACAATTTCTGGCATTTTTTGAACAAGA 1601 CAAAATTCTTTTACGAGGTATATTGCATTGTACTTGGTACGGCTGAGGGAAGTCTGTTGCCCAGCTCTTGCAATGCAGAC 1681 ACATGCCCTGATATCCAGAATTCTGTAGGATAACATCACAGATTGTAATGCTATCAGGTGAAATTATAATTTTATAGAAT 1761 TACTTTATTTATAGGCAGTGGAGGAGACAGAATAATGTAACTGCAACTCATGTCTTTTTTTTCTTTTTTTTTCTTTTTTT 1841 TTGAGGCAGAGCCTCACCCTGTTGCCCAGGCTGGAGTGCAGTGGCATAATCTTGGCTCACGGCAACCTCTGCCTCCCAGG 1921 TTCAAACGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGCACATGCCACCACACCCAGCTAATTTTTGTAT 2001 TTTTAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCTGGTCTCGAACTCCTGACCTTGTGATCTGCTGGCCTCAGCCTC 2081 CCAAAGTCCTGGGATTACAGGTGAGCCACCACGTGCAGCGTAATGCATGTCTTTTAAAAGGGCATCCACAATGATCCAGT 2161 CACTACGTATATGATGAATATGCAGATACAGGAATTATCAGGACTTCCATAATGATGAATATTGTATTGTTGAGGCCATT 2241 GTCAGAGGAAATAATCTAAAGGTTTTGTGAATTCCTGTACTCATTCTGGGCTGTTCTCCTCAAGGTCATTCCTGCATTAA 2321 CAGGAGGAAGATGATAGGGAGAAGGGAGATCTCAGTTCAGTGATGTGGCCTTTGTGACCAGCCAGCCACTTAATCAGGTG 2401 GAAATGGCCTTAGTGCCACATCAATATTTGCTACCGTGGAGGCTAGTTTTCCCACTTAGGGCATGAGAAGAATTGGTGTA 2481 GTCAGTATAGAGTTGCCAAACCTGTTTTCCAAAAATAATGGTAAATCTATATTTTTCTTTTGAACTGCATTTTTTTAATT 2561 ATTATTATTATTTATTTTGAGACGGAGTCTTGCTCTGTTGCCCAGGCTGGATGGAGTGCAGTGGCACGATCTCGGCTCAC 2641 TGCAAGCTCTGCCTCCTGGGTTCACACCATTCTTCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGTGCCCGCCACCA 2721 TACCCAGCTAATTTTTTGTATCTTTACTAGAGATGGGGTTTCACCATGTTAACTAGGATGGTCTCGATCTCCTGACCTCG 2801 TGATCCGCCTGCCTTGGCCTCCCAAAGTGCTGGGATTATAGGCATGAGCCACCGTGCCCAACCTTTTTTTTTTTTTTTTG 2881 AGACAGAGTCTCACTGTCAGCCAGGCTGGAGTGCAGTGGCATGACCTTGGCTCATTGCAACCTCTACCTCCTAGGTTCAA 2961 GCAATTCTCCTGGCTCAGCCTCCCATGTAGGTGGGACTGGAAGCATGTGCCACCATGCCCGGCCAAGTTTTGTATTTTTA 3041 GTAGAGACGGAGTTTTGCCATGTTGGCCAGGCTGATCTTGGACTCCTGACCTCAGGTGATATGCCTGCCTCAGCCTCCCA 3121 GAGTGGTGGGAATACAGGTGTGAGCCACTGCTGCCAGTCTGAAGTATATTTTAAAGCTGTGATGAGTTATAAATGACATT 3201 CAGTAAGCTATGCATATTTAAGCTGTAGCATGTGATAAATCTTGAGTTTCATATAATCCCATGAAACCATTAACATAGTC 3281 ACAATAATGAACTTAACACCTTTATATTTACTTGGAACCTTTTTATAAAGGCTTTCTTTCTGTTCTCCAGACAACCAATG 3361 ATTTACTTTGCTGTACAGTAGAGTACTTTCCATTTTCTGGAATGTTAGATGAGTGATGTAATAAAGTGTTTCCTCTTATA 3441 ATC Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
miRNA:Target | ---- | |||||||||
Validation Method |
|
|||||||||
Conditions | Flp-In T-REx 293-hAGO1 cells | |||||||||
Location of target site | 3'UTR | |||||||||
Original Description (Extracted from the article) |
...
Validation of interactions identified by CLASH suppports their reliability.
... - Helwak A; Kudla G; Dudnakova T; Tollervey D, 2013, Cell. |
|||||||||
miRNA-target interactions (Provided by authors) |
|
|||||||||
Article |
- Helwak A; Kudla G; Dudnakova T; Tollervey D - Cell, 2013
MicroRNAs (miRNAs) play key roles in gene regulation, but reliable bioinformatic or experimental identification of their targets remains difficult. To provide an unbiased view of human miRNA targets, we developed a technique for ligation and sequencing of miRNA-target RNA duplexes associated with human AGO1. Here, we report data sets of more than 18,000 high-confidence miRNA-mRNA interactions. The binding of most miRNAs includes the 5' seed region, but around 60% of seed interactions are noncanonical, containing bulged or mismatched nucleotides. Moreover, seed interactions are generally accompanied by specific, nonseed base pairing. 18% of miRNA-mRNA interactions involve the miRNA 3' end, with little evidence for 5' contacts, and some of these were functionally validated. Analyses of miRNA:mRNA base pairing showed that miRNA species systematically differ in their target RNA interactions, and strongly overrepresented motifs were found in the interaction sites of several miRNAs. We speculate that these affect the response of RISC to miRNA-target binding.
LinkOut: [PMID: 23622248]
|
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
101 hsa-miR-504-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT000044 | DRD1 | dopamine receptor D1 | 2 | 1 | ||||||||
MIRT004457 | VEGFA | vascular endothelial growth factor A | 2 | 1 | ||||||||
MIRT016249 | BAX | BCL2 associated X, apoptosis regulator | 1 | 1 | ||||||||
MIRT016251 | GADD45A | growth arrest and DNA damage inducible alpha | 1 | 1 | ||||||||
MIRT016252 | FAS | Fas cell surface death receptor | 1 | 1 | ||||||||
MIRT016253 | BBC3 | BCL2 binding component 3 | 1 | 1 | ||||||||
MIRT016254 | TP53I3 | tumor protein p53 inducible protein 3 | 1 | 1 | ||||||||
MIRT016255 | TCEAL1 | transcription elongation factor A like 1 | 2 | 1 | ||||||||
MIRT016256 | MDM2 | MDM2 proto-oncogene | 2 | 1 | ||||||||
MIRT016257 | TP53 | tumor protein p53 | 3 | 1 | ||||||||
MIRT041072 | P2RY13 | purinergic receptor P2Y13 | 1 | 1 | ||||||||
MIRT041073 | PPIL1 | peptidylprolyl isomerase like 1 | 1 | 1 | ||||||||
MIRT041074 | ZNF814 | zinc finger protein 814 | 1 | 1 | ||||||||
MIRT041075 | HIST1H2AC | histone cluster 1 H2A family member c | 1 | 1 | ||||||||
MIRT041076 | FEM1A | fem-1 homolog A | 1 | 1 | ||||||||
MIRT041077 | TXNRD1 | thioredoxin reductase 1 | 1 | 1 | ||||||||
MIRT041078 | RAI1 | retinoic acid induced 1 | 1 | 1 | ||||||||
MIRT041079 | SRRM2 | serine/arginine repetitive matrix 2 | 1 | 1 | ||||||||
MIRT041080 | HNRNPAB | heterogeneous nuclear ribonucleoprotein A/B | 1 | 1 | ||||||||
MIRT041081 | PDLIM1 | PDZ and LIM domain 1 | 1 | 1 | ||||||||
MIRT041082 | FAM208B | family with sequence similarity 208 member B | 1 | 1 | ||||||||
MIRT041083 | PSAT1 | phosphoserine aminotransferase 1 | 1 | 1 | ||||||||
MIRT041084 | TMEM8A | transmembrane protein 8A | 1 | 1 | ||||||||
MIRT041085 | RABGAP1 | RAB GTPase activating protein 1 | 1 | 1 | ||||||||
MIRT041086 | BRD2 | bromodomain containing 2 | 1 | 1 | ||||||||
MIRT041087 | C11orf58 | chromosome 11 open reading frame 58 | 1 | 1 | ||||||||
MIRT041088 | CNOT8 | CCR4-NOT transcription complex subunit 8 | 1 | 1 | ||||||||
MIRT041089 | RPL10 | ribosomal protein L10 | 1 | 1 | ||||||||
MIRT041090 | SMCR7L | mitochondrial elongation factor 1 | 1 | 1 | ||||||||
MIRT041091 | CENPBD1 | CENPB DNA-binding domain containing 1 | 1 | 1 | ||||||||
MIRT041092 | SF3B1 | splicing factor 3b subunit 1 | 1 | 1 | ||||||||
MIRT041093 | MTFP1 | mitochondrial fission process 1 | 1 | 1 | ||||||||
MIRT438313 | CDK6 | cyclin dependent kinase 6 | 1 | 1 | ||||||||
MIRT438352 | TFF1 | trefoil factor 1 | 3 | 1 | ||||||||
MIRT443009 | KBTBD12 | kelch repeat and BTB domain containing 12 | 2 | 2 | ||||||||
MIRT448052 | SFRP1 | secreted frizzled related protein 1 | 2 | 2 | ||||||||
MIRT457649 | ZNF69 | zinc finger protein 69 | 2 | 2 | ||||||||
MIRT458626 | TRIM72 | tripartite motif containing 72 | 2 | 2 | ||||||||
MIRT466176 | TMED5 | transmembrane p24 trafficking protein 5 | 2 | 2 | ||||||||
MIRT472583 | NACC1 | nucleus accumbens associated 1 | 2 | 2 | ||||||||
MIRT473576 | MAT2A | methionine adenosyltransferase 2A | 2 | 6 | ||||||||
MIRT485155 | RASL10B | RAS like family 10 member B | 2 | 2 | ||||||||
MIRT490063 | PRRT2 | proline rich transmembrane protein 2 | 2 | 2 | ||||||||
MIRT493015 | NANOS1 | nanos C2HC-type zinc finger 1 | 2 | 2 | ||||||||
MIRT499425 | PLCG2 | phospholipase C gamma 2 | 2 | 11 | ||||||||
MIRT506956 | HOXB3 | homeobox B3 | 2 | 4 | ||||||||
MIRT507100 | GPCPD1 | glycerophosphocholine phosphodiesterase 1 | 2 | 2 | ||||||||
MIRT508101 | ANKRD33B | ankyrin repeat domain 33B | 2 | 4 | ||||||||
MIRT522215 | NR2C2 | nuclear receptor subfamily 2 group C member 2 | 2 | 6 | ||||||||
MIRT530327 | TNFRSF10D | TNF receptor superfamily member 10d | 2 | 2 | ||||||||
MIRT531042 | ZNF502 | zinc finger protein 502 | 2 | 2 | ||||||||
MIRT532580 | GSS | glutathione synthetase | 2 | 2 | ||||||||
MIRT534841 | RAB15 | RAB15, member RAS oncogene family | 2 | 2 | ||||||||
MIRT536820 | HMGN2 | high mobility group nucleosomal binding domain 2 | 2 | 2 | ||||||||
MIRT538303 | CSNK2A1 | casein kinase 2 alpha 1 | 2 | 2 | ||||||||
MIRT546344 | TFAP2C | transcription factor AP-2 gamma | 2 | 2 | ||||||||
MIRT546704 | RORA | RAR related orphan receptor A | 2 | 4 | ||||||||
MIRT549222 | BCL2L11 | BCL2 like 11 | 2 | 4 | ||||||||
MIRT549623 | TMEM101 | transmembrane protein 101 | 2 | 2 | ||||||||
MIRT549931 | NDUFB5 | NADH:ubiquinone oxidoreductase subunit B5 | 2 | 2 | ||||||||
MIRT550163 | ZNF223 | zinc finger protein 223 | 2 | 4 | ||||||||
MIRT550555 | ARSK | arylsulfatase family member K | 2 | 2 | ||||||||
MIRT553402 | TRIM2 | tripartite motif containing 2 | 2 | 4 | ||||||||
MIRT554084 | SNX4 | sorting nexin 4 | 2 | 4 | ||||||||
MIRT556962 | IER3IP1 | immediate early response 3 interacting protein 1 | 2 | 2 | ||||||||
MIRT558525 | CSRNP3 | cysteine and serine rich nuclear protein 3 | 2 | 2 | ||||||||
MIRT558565 | CRLF3 | cytokine receptor like factor 3 | 2 | 4 | ||||||||
MIRT560946 | TPM4 | tropomyosin 4 | 2 | 4 | ||||||||
MIRT561628 | SERBP1 | SERPINE1 mRNA binding protein 1 | 2 | 2 | ||||||||
MIRT562174 | HOXA13 | homeobox A13 | 2 | 2 | ||||||||
MIRT568635 | ACVR2A | activin A receptor type 2A | 2 | 2 | ||||||||
MIRT574908 | Plcg2 | phospholipase C, gamma 2 | 2 | 7 | ||||||||
MIRT575177 | Atg9a | autophagy related 9A | 2 | 2 | ||||||||
MIRT611972 | PKD1 | polycystin 1, transient receptor potential channel interacting | 2 | 2 | ||||||||
MIRT613623 | CLASP1 | cytoplasmic linker associated protein 1 | 2 | 4 | ||||||||
MIRT635830 | OPA3 | OPA3, outer mitochondrial membrane lipid metabolism regulator | 2 | 4 | ||||||||
MIRT637344 | DARS2 | aspartyl-tRNA synthetase 2, mitochondrial | 2 | 4 | ||||||||
MIRT643205 | JAK3 | Janus kinase 3 | 2 | 2 | ||||||||
MIRT650232 | SIGLEC9 | sialic acid binding Ig like lectin 9 | 2 | 2 | ||||||||
MIRT655940 | NDUFA4P1 | NDUFA4, mitochondrial complex associated pseudogene 1 | 2 | 2 | ||||||||
MIRT662021 | ZNF445 | zinc finger protein 445 | 2 | 2 | ||||||||
MIRT662037 | FUT2 | fucosyltransferase 2 | 2 | 2 | ||||||||
MIRT666873 | POU2F2 | POU class 2 homeobox 2 | 2 | 2 | ||||||||
MIRT684310 | TRUB2 | TruB pseudouridine synthase family member 2 | 2 | 2 | ||||||||
MIRT687333 | OSMR | oncostatin M receptor | 2 | 2 | ||||||||
MIRT689008 | ATP6AP1 | ATPase H+ transporting accessory protein 1 | 2 | 2 | ||||||||
MIRT695137 | PRY2 | PTPN13-like, Y-linked 2 | 2 | 2 | ||||||||
MIRT695154 | PRY | PTPN13-like, Y-linked | 2 | 2 | ||||||||
MIRT700695 | POLR3D | RNA polymerase III subunit D | 2 | 2 | ||||||||
MIRT703269 | GNL3L | G protein nucleolar 3 like | 2 | 2 | ||||||||
MIRT708941 | CRY2 | cryptochrome circadian clock 2 | 2 | 2 | ||||||||
MIRT709200 | SAPCD2 | suppressor APC domain containing 2 | 2 | 2 | ||||||||
MIRT709572 | PDE4A | phosphodiesterase 4A | 2 | 2 | ||||||||
MIRT711295 | PSME3 | proteasome activator subunit 3 | 2 | 2 | ||||||||
MIRT712425 | MACROD2 | MACRO domain containing 2 | 2 | 2 | ||||||||
MIRT713941 | PIGR | polymeric immunoglobulin receptor | 2 | 2 | ||||||||
MIRT714124 | TMED9 | transmembrane p24 trafficking protein 9 | 2 | 2 | ||||||||
MIRT714630 | KIAA1143 | KIAA1143 | 2 | 2 | ||||||||
MIRT724046 | SMIM14 | small integral membrane protein 14 | 2 | 2 | ||||||||
MIRT724649 | PKDREJ | polycystin family receptor for egg jelly | 2 | 2 | ||||||||
MIRT725476 | GRAP2 | GRB2-related adaptor protein 2 | 2 | 2 |
miRNA-Drug Associations | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|